Mary Kay Europe Takes Home Prestigious Awards as Champion of Women’s Empowerment and Entrepreneurship, Business Excellence, and Corporate Social Responsibility
10.3.2020 07:00:00 CET | Business Wire | Press Release
Mary Kay Inc., a leading corporate advocate of women’s empowerment and entrepreneurship, announced today that Viktoriia Zoria-Iatsenko, General Manager of Mary Kay Ukraine, received the “Top 25 Business Women in Ukraine” award in the Beauty Industry category from the Vlast Deneg(Power of Money) magazine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200309005647/en/
Tara Eustace – President, Mary Kay Europe Region (Photo: Mary Kay Inc.)
Viktoriia Zoria-Iatsenko‘s recognition is just the latest award in a series of 50 product and industry awards that Mary Kay Europe has brought home in the last year, continuing its commitment to propelling women to leadership roles and developing them for success.
“Mary Kay Europe’s motto is ‘Never Settle For Less Than The Best,’” said Tara Eustace, President of the Mary Kay Europe region. “For several decades, our company has been instrumental in breaking down conventional barriers to empower women to achieve their full potential in business as well as in personal life, helping them believe in themselves so they can utilize their gifts and skills in a wide array of disciplines.” Eustace’s country leadership is comprised of over 80% females.
Below is a snapshot of a few of the accolades:
Excellence in Women’s Leadership, Entrepreneurship and Empowerment
- Mary Kay Russia’s General Manager, Alla Sokolova, received the “Manager of the Year Award” from Russian Business Guide's People of the Year, recognizing her contribution in the development of the Russian economy and entrepreneurship in Russia.
- Mary Kay Spain's General Manager, Gema Aznar, was chosen as one of the “500 Most Influential Women in Spain” in YoDona magazine's annual list. YoDona magazine assembles the most powerful women in Spain in its special edition called “Female Power.”
- The “Secrets of Big Business with Mary Kay®” program created by Mary Kay Russia was recognized as the “2019 Best Social Project of Russia Award” in the “Social Entrepreneurship” category.
Excellence in Corporate Social Responsibility, Compliance
- During its annual gala, Why Story, a Polish national magazine and website that comments on current events in Poland, awarded Mary Kay Inc. with the prestigious “The Best and More” award for its high-quality products and broad corporate social responsibility.
- Mary Kay Moldova received the “TOP Brand 2019” designation in the Cosmetics category in VIP magazine’s “Top 100 Brands 2019” annual edition. VIP magazine awards businesses based on their market innovations and high consumer awareness of its brand and products.
- Mary Kay Spain received the “Best Pyme Award in Compliance Policy” from one of the most respected financial newspapers in Spain, EXPANSIÓN, which selects the best companies in compliance culture on an annual basis.
Excellence in Direct Selling
- Mary Kay Belarus received the “Direct Sales Cosmetic Company Number One Award” from the “Number One” annual national awards, whose task is to promote healthy competition and to determine the best players in the Belarusian market.
- Mary Kay Ukraine was recognized as “Number 1Direct Selling Cosmetic Brand” in the “Favor of Success” survey.
Excellence in Digital Education and Printed Tools
- Mary Kay was recognized in the “2019 Spring Omni Awards” with a coveted gold ranking in the Educational category for its innovative Link & Learn™ sales education system. The e-learning platform hosts a robust learning curriculum designed to amplify educational support for the independent sales force and increase their business success.
- Mary Kay Russia’s MirrorMe™ App won the“2019 Best Corporate Media Award” in the "Client Media: Web Media” category. With the Mary Kay® MirrorMe™ mobile application, anyone can create beautiful makeup without any makeup tools.
- The Applause magazine, which is a Mary Kay educational and motivational monthly publication, became a laureate of the Russian International Competition of Corporate Media “Media Leader 2019” in the nomination “The Best Corporate Magazine.”
- Mary Kay Russia also scored the prestigious award of the National Competition of Russian Corporate Media Resources Silver Threads for the “Mary Kay On People Management” book in the nomination “The Best Corporate Book.”
Product Excellence
With more than 1,500 patents and a team of scientists dedicated to producing innovative products backed by proven results, Mary Kay® products in Europe garnered 35 awards in 2019. Among the products distinguished by the beauty industry and consumers, TimeWise Miracle Set 3D®, TimeWise® 3D Foundations, TimeWise Repair® Lifting Bio-Cellulose Mask, and the newly launched Mary Kay® Hydrogel Eye Patches, were the most rewarded.
Global Recognition
- In 2019, David Holl, Mary Kay CEO was recognized as one of the “10 Most Reputable CEOs in the World” by RepTrak® – Reputation Institute.
- Mary Kay ranked #42 on the 2019 Global Workplace 100 released by Reputation Institute.
- Mary Kay won “Fan Favorite” and “Best in Show” (small category) for its video about domestic violence from the Boston College International Corporate Citizenship Film Festival.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200309005647/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom